



PRO INSTRUMENTS USED IN STUDIES OF PULMONARY HYPERTENSION SINCE 1960

Alison Martin¹ ¹Crystallise Ltd, Essex, UK alison.martin@crystallise.com

Objectives

To create an evidence map of the different patient-reported outcome instruments used in studies of patients with pulmonary arterial hypertension (PAH), the geographical settings in which these studies were conducted and the interventions assessed.

Methods

We searched the heoro.com database (www.heoro.com) for PRO studies on PAH published between 1960 and May 16 2017, and analysed the abstracts identified by the search to determine the different PRO instruments cited across the range of geographical locations and interventions. We presented the findings as an evidence map.

Map of type of PAH by PRO instrument

Results Map of studies by publication year

Year	1960-1999	2000-2004	2005-2010	2011-2015	2015-2017
Abstracts	1	5	25	25	14

 AQ20 – Airways Questionnaire 20 AQOL – Australian Quality of Life BDI – Borg Dyspnoea Index CAMPHOR – Cambridge Pulmonary Hypertension Outcome Review CHD – Congenital heart disease (inc Eisenmenger syndrome) CHFQ – Congestive Heart Failure Questionnaire CHQ-PF50 – Child Health Questionnaire – Parent Form COPD – Chronic obstructive pulmonary disease CTEPH – chronic thromboembolic pulmonary hypertension D-12 – Dyspnoea-12 EQ-5D – EuroQol Questionnaire EscSG – European Scleroderma Study Group activity index ERA – Endothelin receptor antagonist GAD-7 – General Anxiety Disorder Scale HADS – Hospital Anxiety and Depression Scale HAQ-DI – Health Assessment Questionnaire – Disability Index ILD- Interstitial lung disease 	MLHFQ – Minnesota Living with Heart Failure Questionnaire NHP – Nottingham Health Profile PAH – Pulmonary arterial hypertension PAHSIS – PAH Symptom Interference Scale PAH-SSS – PAH Symptom Severity Scale PDE-5 – Phosphodiesterase-5 inhibitor POMS – Profile Of Mood States RSS – Rodnan Skin Score SF-6D – Short Form 6 items SF-12 – Short Form 12 items SF-36 – Short Form 36 items SG – Standard Gamble SGRQ – St. George's Respiratory Questionnaire SLE – Systemic lupus erythematosus TSQM – Treatment Satisfaction Questionnaire for Medication TTO – Time Trade-Off UCSD-SBQ – University of California San Diego Shortness of Breath Questionnaire
KCQ – Kansas City Questionnaire	VAS – Visual Analogue Scale

		AQ20	AQOL	BDI	CAMPHOR	CHFQ	CHQ-PF50	D-12	EmPHasis	EQ-5D	EscSG	GAD-7	HADS	HAQ-DI	КСQ	MLHFQ
С	ТЕРН	0	0	1	0	0	0	0	0	1	0	1	0	0	0	3

Any PAH	1	2	1	7	1	1	1	1	5	1	1	2	0	1	6
ILD	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
CHD	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0
Sarcoid	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Systemic sclerosis	0	0	1	0	0	0	0	0	0	1	0	0	4	0	0
COPD	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
SLE	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Other causes	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	NHP	PAHSIS	PAH-SSS	PHQ-9	POMS	RSS	SF-6D	SF-12	SF-36	SG	SGRQ	TSQM	тто	UCSD- SBQ	VAS
СТЕРН	0	0	0	1	0	0	0	0	6	0	1	0	0	0	0
Any PAH	1	1	1	1	1	0	1	0	25	1		2	1	0	1
ILD	0	0	0	0	0	0	0	0	3	1	1	0	0	1	1
CHD	0	0	0	0	0	0	0	1	3	0		0	0	0	0
Sarcoid	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0
Systemic sclerosis	0	0	0	0	0	2	0	0	2	0	0	0	0	0	0
								•	0	0	2	0	•	•	0
COPD	0	0	0	0	0	0	0	0	2	0	2	0	0	0	0
COPD SLE	0 0	0 0	0 0	0 0	0	0 0	0	0	2 1	0	0	0	0	0	0

Map of geographical location by intervention

	Surgery	Lung transplant	Exercise	Any ERA	Any PDE-5	Acetazolamide	Ambrisentan	Aspirin	Bosentan	Epoprostanol	lloprost	Macitentan	Oxygen	Sildenafil	Simvastatin	Tadalafil	Treprostanil	Other /none
Australia	0	0	0	0	0	0	0	0	3	0	0	0	0	1	0	0	1	1
Belgium	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Brazil	0	0	0	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0
Canada	0	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	1
China	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
France	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	2
Germany	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
Hungary	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
India	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
International	1	0	2	1	0	0	0	0	1	1	0	1	0	1	0	0	0	4
Italy	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Japan	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Korea	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Netherlands	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0
New Zealand	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Portugal	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Spain	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Switzerland	0	0	0	0	0	1	0	0	1	0	0	0	1	0	0	0	0	1
Turkey	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
UK	0	0	0	0	0	0	0	0	1	0	0	0	0	3	0	2	0	4
USA	1	0	1	0	0	0	1	1	0	1	1	0	0	0	1	0	1	8
Unknown	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0

Numbers refer to number of studies identified for each category. Where a study is set in two or three locations, these are all listed separately. Studies set in five or more jurisdictions, or systematic reviews are classified as International. Studies are mapped to all relevant subcategories.

Conclusions

A wide range of PRO tools have been used in studies of PAH, but most used the SF-36 with the US or UK the most common locations.

Crystallise Ltd. Unit 21 Thames Enterprise Centre, Thames Industrial Park, East Tilbury, Essex RM18 8RH, UK Tel: +44 (0)1375 488020

For a copy of this poster or the interactive evidence map, email: alison.martin@crystallise.com



Presented at the ISPOR 20th European Congress 4-8November 2017, Glasgow, Scotland

www.crystallise.com www.heoro.com